CD274 and small cell lung carcinoma: Exploratory analyses of the CheckMate451 study in the CPS-evaluable population demonstrated that PD-L1 expression levels (CPS ≥ 1 or < 1) were not associated with the benefits of nivolumab with or without ipilimumab compared to placebo as first-line maintenance therapy for ES-SCLC.